Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-iT: Prospective Randomized Evaluation of Emerging Novel Treatments for Infection Prophylaxis in Total Joint Replacement (Pilot)
2022-000663-45Phase 3Active
- Sponsor
- Hamilton Health Sciences
- Start
- Nov 2022
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of chlorhexidine, povidone-iodine, vancomycin and sodium chloride in periprosthetic joint infection (PJI) (4 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Feasibility outcomes. Started Nov 2022; status: active.
02
Drugs
chlorhexidinepovidone-iodinevancomycinsodium chloride
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2022-000663-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000663-45.